- LASN01, a fully human, clinical-stage antibody which binds to IL-11R, potently blocks IL-11 signaling to prevent IL-11 driven fibrotic diseases
News Category: Press Releases
- Lassen to also be featured at the ATS Respiratory Innovation Summit
- Industry veteran Dr. Fardis to succeed current CEO Mark Barrett to lead Lassen in its next phase of growth and ongoing advancement of clinical programs
Continue reading “Lassen Therapeutics Appoints Maria Fardis, PhD, MBA, as Chief Executive Officer”
- Anti-IL18BP antibodies inhibit tumor growth in a mouse syngeneic tumor model
- Inhibition of IL18BP/IL18 binding releases immune-stimulatory IL18 to mediate a proinflammatory response in cancer
- Anti-human IL-18BP is a promising novel approach for cancer immunotherapy
- LASN01 targets the immunological drivers of fibrosis
- Inhibition of IL-11 receptor shows anti-fibrotic effect in multiple preclinical models
- Preclinical data support best-in-class potential of LASN01
San Diego, CA, June 15, 2022 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today presented new preclinical data on LASN01, a monoclonal antibody targeting IL-11 receptor (IL-11R), in preclinical models of skin fibrosis at the Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado. The data build upon the results in models of lung fibrosis recently presented at the American Thoracic Society (ATS) conference in May.
San Diego, CA, May 26, 2022 – Lassen Therapeutics, a biotech company developing breakthrough antibody therapeutics as potential treatments for fibrosis, rare diseases and oncology, today announced plans to present a poster on IL-11 receptor-blocking as a novel therapeutic approach for lung fibrosis at the upcoming Keystone Symposia Conference on Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies being held in Keystone, Colorado, June 12-16, 2022.
- LASN01 is a potent inhibitor of IL-11 signaling
- Inhibition of IL-11 receptor shows anti-fibrotic effect in multiple preclinical models
- LASN01 is rapidly advancing toward clinical evaluation
- Lassen selected for oral presentation at ATS scientific sessions and will be featured at the ATS Respiratory Innovation Summit
- Lassen SAB member Cory Hogaboam, Ph.D. from Cedars-Sinai, to present data on IL-11 in idiopathic pulmonary fibrosis at ATS scientific sessions
Dr. Arora brings deep expertise in innovative biopharmaceutical development and experience in inflammation and immunology
Continue reading “Lassen Therapeutics Appoints Puneet S. Arora M.D. as Chief Medical Officer”